Patents Examined by Dennis Heyer
  • Patent number: 11369587
    Abstract: The present invention relates to a pharmaceutical composition of Tecovirimat for injection, comprising Tecovirimat as an active ingredient, cyclodextrin and an additive. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: June 28, 2022
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA China
    Inventors: Wu Zhong, Meiyan Yang, Wei Gong, Yuli Wang, Chunsheng Gao, Xinbo Zhou, Song Li
  • Patent number: 11344516
    Abstract: The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C15-C25) hydroxyalkanoic acid), an antioxidant, and water.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: May 31, 2022
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Drazen Ostovic, Gary Fred Musso
  • Patent number: 11337917
    Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: May 24, 2022
    Assignee: INTERVET INC.
    Inventors: Rainer Roepke, Carsten Schmidt, Susi Alteheld, Carina Hang
  • Patent number: 11331301
    Abstract: A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: May 17, 2022
    Assignees: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center), Mor Research Applications Ltd.
    Inventors: Hinanit Koltai, Yoram Kapulnik, Dvora Namdar, Moran Mazuz, Ido Laish, Timna Naftali
  • Patent number: 11324789
    Abstract: A method of treating equine encephalitis is provided. A composition having at least one cardiac glycoside, such as oleandrin, is used to treat a viral infection causing the encephalitis. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: May 10, 2022
    Assignee: PHOENIX BIOTECHNOLOGY, INC.
    Inventors: Robert A. Newman, Otis C. Addington
  • Patent number: 11312709
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: April 26, 2022
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Anish Bandyopadhyay, Mui Cheung, Hilary Schenck Eidam, Hemant Joshi, Dai-Shi Su
  • Patent number: 11305017
    Abstract: The invention described herein relates to methods and compositions for treating cancer in a patient or a tumor cell by administering an effective amount of an anti-fugetactic agent and an additional anti-cancer agent.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: April 19, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Patrick Reeves
  • Patent number: 11299497
    Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 12, 2022
    Assignee: UNION therapeutics A/S
    Inventors: Jens Larsen, Simon Feldbaek Nielsen, Peter Andersen
  • Patent number: 11292799
    Abstract: The present invention relates to novel substituted azetidine dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 5, 2022
    Assignee: UNION THERAPEUTICS A/S
    Inventors: Mark Andrews, Daniel Rodriguez Greve, Jens Larsen
  • Patent number: 11286268
    Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 29, 2022
    Assignee: eFFECTOR Therapeutics, Inc.
    Inventors: Samuel Sperry, Alan X. Xiang, Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Mike Shaghafi, Theo Michels, Christian Nilewski, Chinh Viet Tran, Garrick Kenneth Packard, Alan Grubbs, Kaveri Urkalan, Takasuke Mukaiyama
  • Patent number: 11285101
    Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 29, 2022
    Assignee: Intervet Inc.
    Inventors: Susi Alteheld, Stefan Fuchs, Carina Hang, J├╝rgen Lutz
  • Patent number: 11285213
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: March 29, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11285151
    Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: March 29, 2022
    Assignee: EMORY UNIVERSITY
    Inventors: Michael G. Natchus, Richard Arrendale, Dennis Liotta, Ketan Desai, Hyunsuk Shim
  • Patent number: 11285214
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: March 29, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11248002
    Abstract: Disclosed are a sesquiterpene derivative and a use of the same in preparation of a medicament for treating hepatitis B diseases. The sesquiterpene derivative has the effects of down-regulating the hepatocyte nuclear factor 4? (HNF-4?) and significantly inhibiting the hepatitis B virus, and can be used for preventing and/or treating and/or assisting in the treatment of liver system diseases and symptoms caused by the hepatitis B virus, and can be used as a hepatic protective agent. In addition, the synthetic sesquiterpene derivative can also be used for preventing or treating viral infectious diseases and conditions resulting from the influenza virus, coxsackievirus, herpes simplex virus, etc. Also involved is the preparation of the synthetic sesquiterpene derivative, which acts as a raw material, in clinically acceptable pharmaceutical formulations, such as oral dosage forms such as tablets, capsules and drop pills or non-oral dosage forms such as inhalants and injections.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: February 15, 2022
    Assignee: KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Min Xu, Haoyang Yuan, Haizhou Li, Yingjun Zhang, Chongren Yang
  • Patent number: 11234973
    Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: February 1, 2022
    Assignees: PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, Agency for Science, Technology and Research
    Inventors: Michael Hayden, Mahmoud Abdulhossein Pouladi
  • Patent number: 11229635
    Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell growth, propagation or malignancy, thrombocytopenia, wound healing, and conditions related to stem cells by the administration of BCN057, 512, or an analog thereof.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 25, 2022
    Assignee: BCN Biosciences L.L.C.
    Inventor: Andrew J. Norris
  • Patent number: 11230547
    Abstract: The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Matthew Christopher, Hua Zhou, David James Witter, Chaomin Li, John Lampe, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu
  • Patent number: 11219624
    Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: January 11, 2022
    Assignee: INCYTE HOLDINGS CORPORATION
    Inventors: Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
  • Patent number: 11213587
    Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 4, 2022
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Arturo Angel, Gordon Dow